Abstract: The invention relates to a method of performing ocular surgery, after an anterior capsulotomy has been made, by forming a sealed expanded capsular bag. The method includes sealing the capsular bag with a viscoelastic material to provide a gas tight seal to prevent leakage into the anterior chamber of the eye during the surgical process; expanding the capsular bag by introducing a gas capable of exerting a pressure on the inner surface of the capsular bag wall; inspecting and/or treating the capsular bag with one or several devices and/or agents suitable for performing inspection and/or treatment. The inspection and/or treatment can comprise any of visual inspection, estimation of capsular bag volume; labeling any residual epithelial cells to detect the presence thereof; removing residual epithelial cells, implanting one or more intracapsular implants; injecting a lens forming material for molding a lens in situ; drying the lens capsule; alone or in any combination.

Abstract: An elongated, rigid cannula has a peripheral wall defining a central bore and a side port for introduction of material into the bore. A covering of resilient, flexible material is provided in the area of the side port, with a corresponding aperture aligned with the port of the cannula. The aperture of the resilient covering can be somewhat smaller than the underlying cannula port, forming a resilient margin that overhangs and surrounds the port.

Abstract: A process for inhibiting vascular proliferation separately introduces components into the eye to generate plasmin in the eye in amounts to induce complete posterior vitreous detachment where the vitreoretinal interface is devoid of cortical vitreous remnants. The process administers a combination of lysine-plasminogen, at least one recombinant plasminogen activator selected from the group consisting of urokinase, streptokinase, tissue plasminogen activator, chondroitinase, pro-urokinase, retavase, metaloproteinase, and thermolysin and a gaseous adjuvant to form a cavity in the vitreous. The composition is introduced into the vitreous in an amount effective to induce crosslinking of the vitreous and to induce substantially complete posterior vitreous detachment from the retina without causing inflammation of the retina.

Abstract: A medical instrument includes a handpiece having irrigation and aspiration channels, a connector coupled to the handpiece by a sliding friction fit and having channels forming continuations of the irrigation and aspiration channels, and a removable tip threadedly coupled to the connector.

Abstract: A device for treating glaucoma in an eye is described. The device includes a body defining a lumen and having first and second ends and external and lumenal surfaces, wherein the body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. The device further includes a filter membrane capable of providing outflow resistance to aqueous humor flowing through the lumen. The device further includes a debris filter positioned either at the first end or between the first end and the filter providing outflow resistance. Methods of treating glaucoma wherein the device is implanted in the sclera of an afflicted eye are also described.

Abstract: A unit dose, gas-filled syringe is provided which is filled with gas and packaged in a gas barrier material prior to use to increase shelf-life, that is, to minimize gas leakage and dilution of the contents of the syringe. The syringe is filled with a selected gas and sealed inside a container made from a high gas barrier material. The container is also filled with the selected gas. The container material is selected to have a gas transmission rate sufficient to prevent the selected gas from diffusing out of the container into the atmosphere. The volume of gas in the container is greater that atmospheric pressure to prevent atmospheric contaminants from entering the container and syringe.

Abstract: Method and apparatus for enhancing the optical transparency of biological tissue covered by a surface permeability barrier of tissue, involving the delivery of a clarifying agent to the target biological tissue to alter the attenuation characteristics of the target biological tissue.

Abstract: A surgical cassette for use in a combined anterior segment and posterior segment ophthalmic surgical procedure is disclosed. The surgical cassette includes an irrigation inlet for receiving irrigation fluid from a source, a first irrigation outlet for providing irrigation fluid to a first ophthalmic microsurgical instrument, a first manifold fluidly coupling the irrigation inlet with the first irrigation outlet, a second irrigation outlet for providing irrigation fluid to a second ophthalmic microsurgical instrument, and a second manifold fluidly coupling the irrigation inlet with the second irrigation outlet. The surgical cassette greatly simplifies the combined procedure by eliminating the need for separate anterior segment and posterior segment cassettes for the combined procedure.

Abstract: Hyaluronic acid is commonly used as a spacer in eye surgeries such as cataract surgery, intraocular lens surgery, corneal transplant surgery and some types of glaucoma surgery. One common side effect of these surgical procedures is a postoperative rise in intraocular pressure which can be serious and can cause permanent loss of function of optic nerve fibers and, therefore, loss of visual field function as well as visual acuity function. Intraoperative and postoperative rises in intraocular pressure also occur in vitreous, retina and other posterior segment surgeries. Methods are provided for reducing the postoperative intraocular pressure in an eye to normal preoperative levels while maintaining the therapeutic effects of the hyaluronic acid.

Abstract: A method and apparatus for presbyopia correction via combination of a surgical and pharmacological means are disclosed. The pharmacological means is to either “trigger” or enhance the contraction effect after a surgical method for larger accommodation and/or for more stable post-surgery results. In addition, the invention discloses that lower dose range is especially useful in providing eye drugs that is low enough to be both safe and effective when used together with the surgical methods. The preferred embodiments for the surgical methods to remove a portion of the sclera tissue include lasers at wavelength of (0 19-0.36) um and (0.9-3.2) um and the non-laser device of radio frequency wave, electrode device, bipolar device and plasma assisted device. The preferred embodiment for pharmacological means includes the use of pilocarpine hydrochloride, phosphorothioate, physostigmine or other beta-adrenergic propanolamines.

Abstract: A glaucoma shunt including first and second porous regions laminated together, and a third region having edge areas fused to edge areas of the second region so as to form a hollow reservoir therebetween. Also included is a catheter having a first end sandwiched between the second and third regions and a second end to be implanted into an anterior region of an eye. A method of making and surgically implanting such a glaucoma shunt is also included.

Abstract: A method of improving vision in an amblyopic eye is described in which vision in the dominant eye is reversibly disrupted. The technique promotes improvement of visual acuity in the weaker eye. The disclosed method is particularly suitable for treatment of adult amblyopia. The method also includes several devices suitable for use in the described treatments.

Abstract: Implantable, pressure adjustable diaphragm pump systems which are scalable and are characterized by a common type of actuating mechanism. The pumps may be inductively and transcutaneously powered via adjacent, mutually inductive electromagnetic coils. Alternatively the pumps may be effectively “self” powered using a synthetic muscle attached to a local bending or twisting force. The pumps may be used in a range of applications from mechanical applications to medical applications such as intraocular pressure control for glaucoma patients, bodily fluid drainage control, and drug delivery systems. These pump systems each include a pumping chamber having an anterior end attached to an implantable influent conduit. In the case of an ocular pressure control device, the influent conduit is inserted into the anterior chamber of the eye.

Abstract: The invention relates to the field of medicine, in particular, to ophthalmology. The technical result of the invention is reduction of the loss of endothelium in the post-operation period, and during post-operation keratopathy and the initial stage of secondary endothelium-epithelium dystrophy—reduction of the edema and normalization of the thickness of the cornea. The technical result is achieved in that in a method of restoring the endothelium of the cornea, including administration of an activating solution into the anterior segment of the eye, in accordance with the invention, restoration of the endothelium of the cornea is effected with the aid of an activating solution having the following composition: carnosine  0.1-20.0 mg a complex of glycosaminoglycans with cations 0.005-0.

Abstract: A process is disclosed for liquefying the vitreous humor of an eye. The process includes the steps of delivering plasmin into the vitreous of the eye and incubating the vitreous and plasmin together for a period of time. Plasmin may be introduced through injection or a sustained release device. Plasmin may be used to treat a pathological condition of the eye such as diabetic retinopathy, macular hole, macular pucker, intraocular infection, foreign intraocular material and retinal detachment.

Abstract: A device for preventing post occlusion flow surges during eye surgery includes an enclosure defining an inlet and an outlet. The enclosure further defines a flow passage between the inlet and the outlet. A restriction is positioned in the flow passage. Structure preferring a filtering function is placed upstream of the restriction for permitting fluid passage through the device. The enclosure further defines a storage area for collecting material restrained by the filter structure. In the preferred embodiment, the device is constructing from a suitable plastic or other molded material, and is intended for disposable use.

Abstract: A device for treating glaucoma in an eye is described. The device includes a body defining a lumen and having first and second ends and external and lumenal surfaces, wherein the body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. The device further includes a filter capable of providing outflow resistance to aqueous humor flowing through the lumen. Methods of treating glaucoma wherein the device is implanted in the sclera of an afflicted eye are also described.

Abstract: An ophthalmological device for cutting into a nucleus of a cataract comprises a phaco tip including a body having at a distal end thereof a solid blade with a face edge adapted to be placed in contact with the nucleus. There is no aspiration port in this face edge. An aspiration port in the body is displaced rearward from the face edge by a distance which is greater than the length of the blade. A sleeve fits over the body and has a forward section that terminates in an opening in advance of the aspiration port. The device is used alternately with a standard phaco tip to remove cataracts. A surgical instrument comprises a handpiece including phaco tip having a face edge having aspiration port therein that is adapted to be placed in communication with a source of aspiration. A control unit regulates the application of aspiration to the aspiration port, enabling aspiration at the aspiration port to be discontinued on command.

Abstract: A process for inhibiting vascular proliferation introduces a composition into the eye inducing posterior vitreous detachment. The composition includes a combination of plasminogen, a collagen crosslinking agent and at least one plasminogen activator selected from the group consisting of urokinase, streptokinase, tissue plasminogen activator, chondroitinase, pro-urokinase, retavase, metaloproteinase, and thermolysin. The composition is introduced into the vitreous in an amount effective to induce crosslinking of the vitreous and to induce substantially complete or partial posterior vitreous detachment from the retina without causing inflammation of the retina. In one embodiment, a gaseous material is introduced into the vitreous before or simultaneously with the composition to compress the vitreous against the retina while the composition induces the posterior vitreous detachment.

Abstract: A method of improving vision in an amblyopic eye is described in which vision in the dominant eye is reversibly disrupted. The technique promotes improvement of visual acuity in the weaker eye. The disclosed method is particularly suitable for treatment of adult amblyopia. The method also includes several devices suitable for use in the described treatments.

Abstract: An ocular iontophoretic device for delivering an aptamer to an affected area of a living being's eye for inhibiting VEGF function therein, the device comprising an active electrode assembly associated with a matrix and/or reservoir, wherein the matrix and/or reservoir includes an aptamer capable of inhibiting VEGF function. A method for treating an affected area of a living being's eye, comprising the steps of: associating an aptamer with an ocular iontophoretic device; positioning at least a portion of an ocular iontophoretic device on the eye of the living being; and iontophoretically delivering the aptamer to an affected area of the living being's eye.

Abstract: A method of staining an ocular structure, the structure being a human or other mammalian eye or portion thereof, the method comprising staining the ocular structure with either indigotindisulfonate, Patent Blue V, Sulphan Blue, tolonium chloride, or Evans Blue. Ocular structures of particular interest are the anterior lens capsule and the vitreo-retinal interface.

Abstract: A spray or delivery device is arranged to dispense a dye into the anterior chamber of a human eye or other mammalian eye for the purpose of staining a specific ocular structure or tissue. An ocular structure of particular interest is the anterior lens capsule. The spray device includes a cannula having a distal end arranged for insertion into the anterior chamber of the eye. The cannula preferably has a dispensing orifice located at a side of the cannula offset from the distal end. The orifice preferably dispenses the fluid dye or stain in spray form. In one exemplary embodiment, the cannula has a fin extending radially outward from the cannula. In another exemplary embodiment, the cannula has a flared sleeve surrounding and extending from the orifice. In a method for conducting intra-ocular surgery, said delivery device would dispense a dye in a particular fashion so as to control its application to the intended target tissue, thereby limiting delivery of the dye to undesired surrounding tissue structures.

Abstract: A surgical cassette for use in a combined anterior segment and posterior segment ophthalmic surgical procedure is disclosed. The surgical cassette includes an irrigation inlet for receiving irrigation fluid from a source, a first irrigation outlet for providing irrigation fluid to a first ophthalmic microsurgical instrument, a first manifold fluidly coupling the irrigation inlet with the first irrigation outlet, a second irrigation outlet for providing irrigation fluid to a second ophthalmic microsurgical instrument, and a second manifold fluidly coupling the irrigation inlet with the second irrigation outlet. The surgical cassette greatly simplifies the combined procedure by eliminating the need for separate anterior segment and posterior segment cassettes for the combined procedure.

Abstract: The invention relates to a visco-elastic composition for use in ocular surgery and to a method of using said composition. Specifically, the present visco-elastic composition comprises a visco-elastic substance and at least one vital dye. The invention enables a visual distinction of the visco-elastic composition from the surrounding aqueous or intraocular structures during ocular surgery, so that the amount present within the eye, the location and the effects of the visco-elastic material can be better monitored.

Abstract: The invention provides a miniaturized, implantable drug delivery device and a method of delivering over a prolonged period of time one or more drugs using such a device. The drug delivery device can be adapted for attachment to the outer surface of an eye. Once attached to the outer surface of an eye, the device can deliver one or more drugs directly into the eye for preventing or ameliorating the symptoms of a particular ocular disorder.

Abstract: The present invention provides a microfistula tube including a soluble duct, defining a drainage canal having an inner surface, the duct being biocompatible, wherein the microfistula tube is coated with and/or incorporates biological for forming a basement membrane, or an intracellular matrix and a basement membrane. The biological cells may coat the inner surface of the drainage canal, and the microfistula tube may be made of a mouldable material or an absorbable material. The invention also provides an implantation system for the microfistula tube including a microfistula tube and a surgical instrument including an outer tube for penetrating body tissue, an inner tube, and an innermost rod, wherein the outer tube, the inner tube and the innermost rod are coaxial, the outer tube is adapted to receive said microfistula tube, whereby the inner tube may be used to push the microfistula tube into position and the innermost rod provides mechanical support during implantation of the microfistula tube.

Abstract: Non-aspirating viscoelastics, compositions and methods of use are disclosed. The non-aspirating, transitional viscoelastics possess sufficient viscosity to be useful in ophthalmic viscosurgery, but may be left in the eye with little or no resulting IOP spike.

Abstract: Surgical methods and related medical devices for treating glaucoma are disclosed. The method comprises trabecular bypass surgery, which involve bypassing diseased trabecular meshwork with the use of a seton implant. The seton implant is used to prevent a healing process known as filling in, which has a tendency to close surgically created openings in the trabecular meshwork. The surgical method and novel implant are addressed to the trabecular meshwork, which is a major site of resistance to outflow in glaucoma. In addition to bypassing the diseased trabecular meshwork at the level of the trabecular meshwork, existing outflow pathways are also used or restored. The seton implant is positioned through the trabecular meshwork so that an inlet end of the seton implant is exposed to the anterior chamber of the eye and an outlet end is positioned into fluid collection channels at about an exterior surface of the trabecular meshwork or up to the level of aqueous veins.

Abstract: A method for treatment of residual lens epithelial cells is disclosed. The method provides increased safety during local treatment in ocular surgery by improved administration of active agents. The method is particularly useful in treatment of proliferative events in ocular surgery, such as posterior capsular opacification.

Abstract: An ocular iontophoretic device for delivering a composition to an affected area of a living being's eye comprising an active electrode assembly associated with a matrix, wherein the matrix includes a composition capable of treating inflammatory and/or neovascularization conditions.

Abstract: A delivery device that allows for the sustained release of an agent, particularly useful for the sustained release of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. The delivery device is minimally invasive, refillable and may be easily fixed to the treatment area. The delivery device includes a hollow body with an inlet port at its proximal end for insertion of the agent, a reservoir for holding the agent and a delivery mechanism for the sustained delivery of the agent from the reservoir to the patient.

Abstract: The invention relates to a method of performing ocular surgery, after an anterior capsulotomy has been made, by forming a sealed expanded capsular bag. The method includes sealing the capsular bag with a viscoelastic material to provide a gas tight seal to prevent leakage into the anterior chamber of the eye during the surgical process; expanding the capsular bag by introducing a gas capable of exerting a pressure on the inner surface of the capsular bag wall; inspecting and/or treating the capsular bag with one or several devices and/or agents suitable for performing inspection and/or treatment. The inspection and/or treatment can comprise any of visual inspection, estimation of capsular bag volume; labeling any residual epithelial cells to detect the presence thereof; removing residual epithelial cells, implanting one or more intracapsular implants; injecting a lens forming material for molding a lens in situ; drying the lens capsule; alone or in any combination.

Abstract: Devices and devices for the treatment of the eye are disclosed. Preferred devices of the invention include a piercing member that is inserted into the eye to create a pathway for a cannula. The cannula is slidably mounted to the piercing member and is adapted to reach a treatment site within the eye at which material is injected into and/or withdrawn from the eye. The outer diameter of the piercing member is small enough to allow for self-sealing of the insertion site of the device upon the device's withdrawal therefrom. Also disclosed are methods for the utilizing the devices to treat the eye.

Abstract: A unit dose, gas-filled syringe is provided which is filled with gas and packaged in a gas barrier material prior to use to increase shelf-life, that is, to minimize gas leakage and dilution of the contents of the syringe. The syringe is filled with a selected gas and sealed inside a container made from a high gas barrier material. The container is also filled with the selected gas. The container material is selected to have a gas transmission rate sufficient to prevent the selected gas from diffusing out of the container into the atmosphere. The volume of gas in the container is greater that atmospheric pressure to prevent atmospheric contaminants from entering the container and syringe.

Abstract: The invention is directed to an implantable device to enable delivery of drugs to the retina. The device minimizes stress to the retina by virtue of its softness and smooth shape that conform to the retina. Drugs are delivered by osmosis or by the device dissolving. It may be connected to an externally mounted pump and drug reservoir that control the amount of drug. It contains one or more holes that are positioned to deliver drugs to the desired location. Drugs may stimulate the retina to enable vision in blind patients. Drugs may be injected directly inside the eye by a trans-scleral pump and valve drug delivery device.

Abstract: A method for treatment of residual lens epithelial cells is disclosed. The method provides increased safety during local treatment in ocular surgery by improved administration of active agents. The method is particularly useful in treatment of proliferative events in ocular surgery, such as posterior capsular opacification.

Abstract: In preferred aspects the invention provides an in-line humidifier, a system using such a humidifier and methods related thereto, a method for infusing a gas into an eye during retinal detachment surgical procedure and a method for treating a retinal tear. The method for infusing gas includes providing an in-line humidifier, humidifying the gas in the in-line humidifier by flowing the gas there through and infusing the humidified gas into the eye. The in-line humidifier includes a housing and a humidifier section disposed within the housing, the humidifier section including a hydroscopic material that releasably retains liquid therein. The housing includes an inlet and outlet connection in fluid communication with the housing interior.

Abstract: A method is disclosed for creating a separation of posterior cortical vitreous from the retina of the eye. The method includes the step of introducing plasmin into the vitreous humor of the eye. The plasmin may be introduced either by injection or through a sustained release device. Optionally, other enzymes, polysaccharides, and/or glycoproteins are intermixed with the plasmin.

Abstract: A device and method are provided for improved treatment of elevated intraocular pressure due to glaucoma. A trabecular shunting device is adapted for implantation within the trabecular meshwork of an eye such that aqueous humor flows controllably from the anterior chamber of the eye to Schlemm's canal, bypassing the trabecular meshwork. The trabecular shunting device may utilize a quantity of pharmaceuticals effective in treating glaucoma, which are controllably released from the device into cells of the trabecular meshwork and/or Schlemm's canal. Depending upon the specific treatment contemplated, pharmaceuticals may be utilized in conjunction with the trabecular shunting device such that aqueous flow either increases or decreases as desired. Placement of the trabecular shunting device within the eye, and release of a glaucoma medication therefrom, can arrest or slow the progression of glaucoma.

Abstract: An ocular iontophoretic device for delivering an aptamer to an affected area of a living being's eye for inhibiting VEGF function therein, the device comprising an active electrode assembly associated with a matrix and/or reservoir, wherein the matrix and/or reservoir includes an aptamer capable of inhibiting VEGF function.

Abstract: Microchip device arrays that can conform to a curved surface are provided for the controlled release or exposure of reservoir contents. The arrays comprise two or more microchip device elements, each of which includes a plurality of reservoirs that contain molecules for controlled release or components for selective exposure, and a means for flexibly connecting the device elements. The reservoirs can contain one or more drugs and/or one or more secondary devices, such as a sensor or a component thereof. Preferably, the microchip devices contain and controllably release therapeutic, prophylactic, and diagnostic molecules to and into the eye of a patient in need thereof.

Abstract: An ocular iontophoretic device for delivering an interferon to an affected area of a living being's eye comprising an active electrode assembly associated with a matrix, wherein the matrix includes an interferon capable of treating viral, immunoregulatory, and/or neovascularization conditions.

Abstract: An ocular iontophoretic device for delivering an aptamer to an affected area of a living being's eye for inhibiting VEGF function therein, the device comprising an active electrode assembly associated with a matrix and/or reservoir, wherein the matrix and/or reservoir includes an aptamer capable of inhibiting VEGF function.

Abstract: Disclosed is a method and apparatus for delivering a drug formulation to a human eye. The method includes the steps of inserting the apparatus below the Tenon's capsule and above the sclera at a point posterior to the limbus of the eye and injecting the drug formulation to form a drug depot on an outer surface of the sclera. The apparatus includes a cannula having a distal portion, a proximal portion, and a bend separating the distal portion and the proximal portion. The distal portion has a radius of curvature substantially equal to a radius of curvature of the globe of the eye. A tangent of the distal portion at the bend is disposed at an angle no more than about 56 degrees with respect to the proximal portion.

Abstract: An apparatus and method for safely cannulating a retinal blood vessel is described. The apparatus consists of a micropipette,micromanipulator and positioner mounted to a base which is attached to a wrist rest commonly used in eye surgery. The micropipette is connected to tubing such that a medication may be injected through the micropipette into the blood vessel or conversely, a small quantity of material may be removed from a blood vessel. Alternatively, a catheter, wire or stent may be placed through the cannula to treat or diagnose an area remote from the insertion site. The ability to cannulate a retinal blood vessel should be efficacious in the treatment of vein and artery occlusion, ocular tumors and other retinal, vascular and optic nerve disorders that would benefit from diagnosis and/or treatment.

Abstract: Intrascleral injection of a therapeutic or diagnostic material at a location overlying the retina provides a minimally invasive technique for delivering the agent to the posterior segment of the eye. The procedure also allows for close proximity of the material to the targeted site and can be effectively used to treat conditions associated with the posterior segment of the eye, including macular degeneration, vein occlusion, and diabetic retinopathy. The sclera can be used to hold a depot of the material such as for sustained released or as a conduit for propelling material through whereby the material is delivered immediately to the underlying tissues but without physically penetrating the sclera with an instrument or otherwise unreasonably traumatizing the eye.

Abstract: Intrascleral injection of a therapeutic or diagnostic material at a location overlying the retina provides a minimally invasive technique for delivering the agent to the posterior segment of the eye. The procedure also allows for close proximity of the material to the targeted site and can be effectively used to treat conditions associated with the posterior segment of the eye, including macular degeneration, vein occlusion, and diabetic retinopathy.

Abstract: An iontophoretic apparatus for ocular iontophoresis comprising a housing element formed to cooperate with the eye. In cooperation with the housing element is a flexible current distribution element that is capable of transmitting electrical current. Coupled to the current distribution element is a conformable medicament containment element that is filled with a medicament which is released under the influence of an electrical current, while a barrier element is provided that is configured to reduce current flow outside of the barrier and aid in the preferential delivery of medicament.

Abstract: An therapeutic agent delivery device that can allows is particularly suitable for delivery of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. Preferred devices of the invention are minimally invasive, refillable and may be easily fixed to the treatment area. Preferred delivery devices of the invention also include those that comprise a non-linear shaped body member body housing one or more substances and a delivery mechanism for the sustained delivery of the one or more substances from the non-linear shaped body member to the patient.